Valor202020212022202320242025TTMGastos comerciales, generales y administrativos538.83 M560.98 M605.75 M689.75 M645.24 M701.52 M701.52 MInvestigación y desarrollo394.59 M406.53 M393.84 M270.81 M245.33 M323.96 M323.96 MBeneficio operativo-112.43 M-29.29 M-142.26 M414.12 M420.64 M253.96 M253.96 MTotal de ingresos no operativos15.89 M-10.02 M-25.04 M7.4 M23.11 M37.49 M37.49 MGastos por intereses, netos de intereses capitalizados8.66 M11.22 M13.04 M23.03 M22.58 M12.28 M12.28 MIngresos no operativos, una vez deducidos los gastos por intereses-6.41 M-21.46 M-40.2 M-15.21 M-2.71 M20.75 M20.75 MIngresos/gastos extraordinarios13.64 M219 K2.12 M-425 K3.24 M4.47 M4.47 MBeneficio antes de impuestos-96.54 M-39.31 M-167.3 M421.52 M443.75 M291.45 M291.45 MParticipación en los beneficios———————Impuestos14.32 M8.86 M-9.04 M-97.64 M71.61 M49.79 M49.79 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-2.51 M-1.6 M-5.53 M-6.33 M-4.51 M-5.31 M-5.31 MBeneficio neto antes de actividades interrumpidas-110.86 M-48.17 M-158.27 M519.16 M372.14 M246.73 M240.9 MOperaciones suspendidas———-163.4 M-5.07 M-5.07 M—Beneficio neto-110.86 M-48.17 M-158.27 M355.76 M367.07 M241.66 M241.66 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-110.86 M-48.17 M-158.27 M355.76 M367.07 M241.66 M241.66 MBeneficio básico por acción——-0.972.142.221.471.47Beneficio por acción diluido——-0.972.12.171.431.43Número medio de acciones ordinarias——163.54 M166.22 M165.39 M164.7 M658.15 MAcciones diluidas——163.54 M169.73 M169.2 M168.74 M674.35 MEBITDA-30.57 M49.37 M-64.4 M489.05 M449.17 M281.12 M281.12 MEBIT-112.43 M-29.29 M-142.26 M414.12 M420.64 M253.96 M253.96 MCosto de los ingresos178.32 M197.39 M218.11 M253.04 M245.33 M196.46 M196.46 MOtros costes de producción———————Amortización y depreciación (flujo de caja)81.85 M78.65 M77.86 M74.93 M28.53 M27.16 M27.16 M
Alkermes plc
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.